About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

Deerfield Management Company Announces up to a $60 million Facility with KemPharm, Inc.

NEW YORK –(BUSINESS WIRE)  – June 3, 2014– Deerfield Management Company announced today it has committed to invest up to $60 million in KemPharm, Inc. through a $10 million senior secured convertible note and a $50 million senior secured term debt facility. The facility provides KemPharm with capital to fund its clinical and regulatory operations and to advance its lead product candidate, KP201, toward regulatory approval and initiate commercialization.  KP201 is being developed as an abuse-deterrentopioid analgesic.

At the initial closing of the transaction, Deerfield funded $15 million of the term loan and $10 million of the convertible notes.  KemPharm may access the remaining $35 million of the term debt upon completion of certain milestones.  Additionally,in accordance with the financing agreement, Jonathan S. Leff, Partner with Deerfield Management, has been named to KemPharm’s Board of Directors.

Mr. Leff remarked, “We believe that KP201 and the rest of KemPharm’s abuse-deterrent prodrugs could play an important role in helping to address the epidemic of opioid abuse.  We are pleased to partner with KemPharm to advance the company’s programs to potential FDA approval and commercialization.” 

Travis C. Mickle, Ph.D., President and CEO of KemPharm, commented, “This financial commitment by Deerfield significantly strengthens KemPharm and enables the rapid advancement of KP201 and our abuse-deterrent product pipeline.  KemPharm now has the financial and strategic backing of a leading healthcare investment firm, which we intend to fully leverage as we deploy our prodrug technology to help address the limitations of existing opioid therapeutics and the epidemic problem of opioid abuse.”

 “This financing provides KemPharm with the near-term capital required to advance our corporate and clinical goals,while providing us with additional flexibility to pursue opportunities that could further propel the value potential of the company. We look forward to benefitting from Deerfield’s wealth of industry and capital markets expertise” concluded Gordon K. “Rusty” Johnson, COO and CFO of KemPharm.

About KemPharm

KemPharm is a biopharmaceutical company focused on the discovery and development of new chemical entities(NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach.  The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high-need areas of pain, ADHD and other CNS diseases.  For more information on KemPharm, please visit the company’s website at

About Deerfield

Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.

For more information, please visit


Deerfield Management Company
Karen Heidelberger, 212-692-7140
[email protected]